Xeris Biopharma Holdings Inc expected to post a loss of 10 cents a share - Earnings Preview

Xeris Biopharma Holdings

04/03/2024 15:05

* Xeris Biopharma Holdings Inc  XERS.OQ   XERS.O  is
expected
to show a rise in quarterly revenue when it reports  results on
March 6 for the period ending December 31 2023
    * The Chicago Illinois-based  company is expected to report
a
31.4% increase in revenue to $43.552 million from $33.14 million
a year ago, according to the mean estimate from 4 analysts,
based on LSEG data. (Majority basis is on Total Revenue basis)
    * ​LSEG's mean analyst estimate for Xeris Biopharma Holdings
Inc
is for a loss of 10 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Xeris
Biopharma
Holdings Inc is $4.50​, above​ its last closing price of $3.18.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.12       -0.12      -0.09     Beat    22.4
 Jun. 30 2023  -0.13       -0.13      -0.14     Missed  -9.8
 Mar. 31 2023  -0.17       -0.17      -0.12     Beat    28.4​
 Dec. 31 2022  -0.16       -0.16      -0.10     Beat    36.5
 ​​Sep.        -0.17       -0.16      -0.16     Met     3
 30 2022                                                
 Jun. 30 2022  -0.23       -0.23      -0.19     Beat    17.4​
 Mar. 31 2022  -0.26       -0.25      -0.25     Met     1.6
 Dec. 31 2021  -0.20       -0.24      -0.42     Missed  -72.1
 This summary was machine generated March 4 at 15:05 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)